『5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer』のカバーアート

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

  • Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
    • Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
  • Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
    • Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
    • Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
  • Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
    • VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
  • Selective review of trials of oral SERDs in the adjuvant setting (11:27)
    • A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054

CME information and select publications

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancerに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。